ПРИМЕНЕНИЕ ПЕРАМПАНЕЛА В ЛЕЧЕНИИ ЭПИЛЕПСИИ: ОБЗОР ЛИТЕРАТУРЫ И ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ

Обложка

Цитировать

Полный текст

Об авторах

К. Ю. Мухин

Институт детской неврологии и эпилепсии имени Святителя Луки, Москва

Автор, ответственный за переписку.
Email: center@epileptologist.ru

Контакты: Константин Юрьевич Мухин -  143396, Москва, пос. Первомайское, дер. Пучково, ул. Светлая, 6

Россия

О. А. Пылаева

Институт детской неврологии и эпилепсии имени Святителя Луки, Москва

Email: fake@neicon.ru
Россия

Список литературы

  1. Власов П.Н. Клинический случай применения Файкомпы. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):5. [Vlasov P.N. Clinical case of application of Fycompa. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2014;(special issue):5. (In Russ.)].
  2. Жидкова И.А. Управление нежелательными явлениями, возникающими на фоне приема перампанела. Эпилепсия и пароксизмальные состояния 2014; (спецвыпуск):13–4. [Zhidkova I.A. Management of undesirable adverse effects that arise on the background of perampanel intake. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2014;(special issue):13–4. (In Russ.)].
  3. Мухин К.Ю., Пылаева О.А. Применение перампанела (Файкомпы) в лечении эпилепсии (опыт Института детской неврологии и эпилепсии им. Святителя Луки). Русский журнал детской неврологии 2014;9(4):14–9. [Mukhin K.Yu., Pylaeva O.A. Perampanel (Fycompa) for treatment of epilepsy (experience of the Svt. Luka’s institute of child neurology and epilepsy). Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2014;9(4):14–9. (In Russ.)]. doi: 10.17650/2073-8803-2014-9-4-14-19.
  4. Мухин К.Ю., Пылаева О.А., Миронов М.Б. Применение перампанела у ребенка с резистентной эпилепсией при синдроме Ангельмана. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):15. [Mukhin K.Yu., Pylaeva O.A., Mironov M.B. Perampanel for children with resistant epilepsy of the Angelman syndrome. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2014;(special issue):15. (In Russ.)].
  5. Перунова Н.Ю. Клинический случай применения Файкомпы. Эпилепсия и пароксизмальные состояния 2014;(спецвыпуск):9. [Perunova N.Yu. Clinical case of application of Fycompa. Epilepsiya i paroksizmal’nye sostoyaniya = Epilepsy and Paroxysmal States 2014;(special issue):9. (In Russ.)]
  6. Пылаева О.А., Мухин К.Ю. Применение нового антиэпилептического препарата перампанел (Файкомпа) в лечении эпилепсии (обзор зарубежной литературы). Русский журнал детской неврологии 2014;9(3): 36–42. [Pylaeva O.A., Mukhin K.Yu. Use of the new antiepileptic drug perampanel (Fycompa) in the treatment of epilepsy: a review of foreign literature. Russkiy zhurnal detskoy nevrologii = Russian Journal of Child Neurology 2014;9(3):36–42. (In Russ.)] doi: 10.17650/2073-8803-2014-9-3-36-42.
  7. Besag F.M., Patsalos P.N. Clinical efficacy of perampanel for partial-onset and primary generalized tonic-clonic seizures. Neuropsychiatr Dis Treat 2016;12:1215–20. doi: 10.2147/NDT.S83842.
  8. Blümcke I., Vinters H.V., Armstrong D. et al. Malformations of cortical development and epilepsies: neuropathological findings with emphasis on focal cortical dysplasia. Epileptic Disord 2009;11(3):181–93. doi: 10.1684/epd.2009.0261.
  9. Franco V., Crema F., Iudice A. et al. Novel treatment options for epilepsy: focus on perampanel. Pharmacol Res 2013;70(1):35–40. DOI: 10.1016/j. phrs.2012.12.006.
  10. French J.A., Krauss G.L., Biton V. et al. Adjunctive perampanel for refractory partialonset seizures: randomized phase III study 304. Neurology 2012;79(6):589–96. DOI: 10.1212/ WNL.0b013e3182635735.
  11. French J.A., Krauss G.L., Steinhoff B.J. et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2013;54(1):117–25. doi: 10.1111/j.1528-1167.2012.03638.x.
  12. Guerrini R., Parrini E. Epilepsy and malformations of the cerebral cortex. In: Epileptic syndromes in infancy, childhood and adolescence. 5th ed. with video. Ed. by M. Bureau, P. Genton, C. Dravet et al. Paris: John Libbey Eurotext, 2012. Pp. 607–29.
  13. Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov 2014;9(4):449–58. doi: 10.1517/17460441.2014.891580.
  14. Hintz M., Nawratil S., Schulze-Bonhage A. Perampanel as a therapy option in patients with epilepsy. Nervenarzt 2016. [Epub ahead of print]. doi: 10.1007/s00115-016-0131-z.
  15. Kerling F., Kasper B.S. Efficacy of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl 2013;(197):25–9. doi: 10.1111/ane.12101.
  16. Ko D., Ramsay R.E. Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures. Acta Neurol Scand Suppl 2013;(197):36–43. doi: 10.1111/ane.12103.
  17. Krauss G.L., Perucca E., Ben-Menachem E. et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: Results from phase III extension study 307. Epilepsia 2014;55(7):1058–68. doi: 10.1111/epi.12643.
  18. Krauss G.L., Perucca E., Ben-Menachem E. et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partialonset seizures: interim results from phase III, extension study 307. Epilepsia 2013;54(1):126– 34. doi: 10.1111/j.1528-1167.2012.03648.x.
  19. Krauss G.L. Perampanel: a selective AMPA antagonist for treating seizures. Epilepsy Curr 2013;13(6):269–72. doi: 10.5698/1535-7597-13.6.269.
  20. Krauss G.L., Serratosa J.M., Villanueva V. et al. Randomized phase III study 306: adjunctive perampanel for refractory partialonset seizures. Neurology 2012;78(18):1408– 15. doi: 10.1212/WNL.0b013e318254473a.
  21. Krauss G.L., Bar M., Biton V. et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125(1):8–15. doi: 10.1111/j.1600-0404.2011.01588.x.
  22. Kwan P., Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9(7):464–8. doi: 10.1053/seiz.2000.0442.
  23. Kwan P., Brodie M.J. Refractory epilepsy: mechanisms and solutions. Expert Rev Neurother 2006;6(3):397–406. doi: 10.1586/14737175.6.3.397.
  24. Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) – Part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet 2013;52(11):927–66. doi: 10.1007/s40262-013-0087-0.
  25. Patsalos P.N. Drug interactions with the newer antiepileptic drugs (AEDs) – Part 2: pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmacokinet 2013;52(12):1045–61. doi: 10.1007/s40262-013-0088-z.
  26. Rektor I., Krauss G.L., Bar M. et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126(4):263–9. doi: 10.1111/ane.12001.
  27. Rheims S., Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatr Dis Treat 2013;9:629–37. doi: 10.2147/NDT.S30129.
  28. Rogawski M.A. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011; 11(2):56–63. doi: 10.5698/1535-7511-11.2.56.
  29. Rohracher A., Brigo F., Höfler J. et al. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother 2016;17(10):1403–11. doi: 10.1080/14656566.2016.1195810.
  30. Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia 2014;55 Suppl 1:13–5. doi: 10.1111/epi.12504.
  31. Satlin A., Kramer L.D., Laurenza A. Development of perampanel in epilepsy. Acta Neurol Scand Suppl 2013;(197):3–8. doi: 10.1111/ane.12098.
  32. Serratosa J.M., Villanueva V., Kerling F., Kasper B.S. Safety and tolerability of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl 2013;(197):30–5. doi: 10.1111/ane.12102.
  33. Shih J.J., Tatum W.O., Rudzinski L.A. New drug classes for the treatment of partial onset epilepsy: focus on perampanel. Ther Clin Risk Manag 2013;9:285–93. doi: 10.2147/TCRM.S37317.
  34. Singh K., Shah Y.D., Luciano D. et al. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study. Epilepsy Behav 2016;61:41–5. doi: 10.1016/j.yebeh.2016.05.007.
  35. Steinhoff B.J., Bacher M., Bast T. et al. First clinical experiences with perampanel – the Kork experience in 74 patients. Epilepsia 2014;55 Suppl 1:16–8. doi: 10.1111/epi.12492.
  36. Steinhoff B.J., Ben-Menachem E., Ryvlin P. et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013;54(8):1481–9. doi: 10.1111/epi.12212.
  37. Steinhoff B.J., Hamer H., Trinka E. et al. A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria. Epilepsy Res 2014;108(5):986–8. doi: 10.1016/j.eplepsyres.2014.03.015.
  38. Steinhoff B.J. Efficacy of perampanel: a review of pooled data. Epilepsia 2014;55 Suppl 1:9–12. doi: 10.1111/epi.12493.
  39. Wang Z.R., Alexopoulos A., Jones S.E. et al. The pathology of magnetic-resonance-imagingnegative epilepsy. Mod Pathol 2013;26(8):1051–8. doi: 10.1038/modpathol.2013.52.
  40. Watanabe K., Negoro T., Aso K. et al. Childhood-onset epilepsy due to focal cortical dysplasia. In: Dysplasias of cerebral cortex and epilepsy. Ed. by R. Guerrini, F. Andermann, R. Canapicchi et al. Philadelphia: Lippincott – Raven Publishers, 1996. Pp. 227--34.
  41. Zwart R., Sher E., Ping X. et al. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl4-isoxazolepropionic acid receptors for the treatment of epilepsy: studies in human epileptic brain, non-epileptic brain, and in rodent models. J Pharmacol Exp Ther 2014;351(1): 124–33. doi: 10.1124/jpet.114.212779.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 22926 от  12.01.2006.